Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Boston Convention and Exhibition Center

Jun 23, 2013 8:30 AM - Jun 27, 2013 12:45 PM

415 Summer Street, , Boston, MA 02210 , USA

DIA 2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Science

TransCelerate’s Collaborative Approach to Risk-based Monitoring: The Methodology

Session Chair(s)

Craig A Wozniak

Craig A Wozniak

Head, Americas Clinical Operations

GlaxoSmithKline, United States

TransCelerate BioPharma Inc. (TransCelerate) developed a methodology for monitoring that shifts monitoring processes from an excessive concentration on source data verification to comprehensive risk-driven monitoring. This philosophical shift in monitoring processes employs centralized and offsite mechanisms to identify and monitor important study parameters holistically and uses adaptive onsite monitoring to further support subject safety and data quality.

Learning Objective : Discuss the methodology developed by TransCelerate members for quality risk management and risk-based monitoring implementation; Describe the processes, tools and operational considerations for implementation of this approach.

Speaker(s)

Craig A Wozniak

TransCelerate: Overview of Organization and Risk-based Monitoring Methodology

Craig A Wozniak

GlaxoSmithKline, United States

Head, Americas Clinical Operations

Michael B. Luker, MBA

Pilot Implementation: Practical Experience to Date

Michael B. Luker, MBA

Eli Lilly and Company, United States

Senior Advisor

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.